Revolution Medicines Q3 EPS $(1.90) Beats $(2.42) Estimate, Sales $197.559M May Not Be Comparable To $23.495M Estimate
Benzinga Newsdesk 5 hours ago
NewsEarningsEarnings Beats
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(2.42) by 21.49 percent. This is a 18.01 percent decrease over losses of $(1.61) per share
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(2.42) by 21.49 percent. This is a 18.01 percent decrease over losses of $(1.61) per share from the same period last year. The company reported quarterly sales of $197.559 million which beat the analyst consensus estimate of $23.495 million by 740.86 percent.